Subcutaneous Injection of Genetically Engineered Exosomes for Androgenic Alopecia Treatment
May 2025
in “
OPAL (Open@LaTrobe) (La Trobe University)
”
New to Minoxidil? There is a guide in the encyclopedia. Read the guide → Studysummary This study found that the multifunctional exosome-based delivery platform EX104 reversed hair follicle miniaturization and promoted hair growth in a mouse model of androgenetic alopecia, performing comparably to minoxidil while also enhancing capillary growth and follicular proliferation.
Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
The study investigates a novel treatment for androgenetic alopecia (AGA) using a genetically engineered exosome-based delivery platform called EX104. Developed from HEK-293 cells, EX104 expresses therapeutic molecules like WNT10B, VEGFA, and FGF7, which reverse hair follicle miniaturization caused by DHT-induced dermal papilla cells. In a murine model, EX104 significantly promoted hair growth by remodeling the follicular microenvironment and restoring miniaturized follicles. It showed comparable hair growth effects to minoxidil but was superior in stimulating capillary growth and follicular proliferation, making EX104 a promising strategy for AGA management and follicular regeneration.
